In Silico Study Evaluates Bioactive Compounds for Inhibiting P. falciparum Glutathione Reductase, Suggesting Antimalarial Potential.
The current study employed integrated in silico methods to assess the biological activity of phytochemical compounds from Morinda lucida as potential inhibitors of P. falciparum Glutathione Reductase (PfGR). In all, 100 phytochemicals were screened using the Prediction of Activity Spectra for Substance (PASS). Then, Pharmacokinetics and Toxicity assessment were conducted using the SwissADMET and pkCSM servers. Subsequently, the selected phytochemicals were subjected to Molecular Docking, Density Functional Theory (DFT) studies, Molecular Dynamics Simulation, and MM/PBSA Binding Energy Analysis. The molecular docking with DFT study indicated that the 4-Hydroxyphenyl-3-nitrobenzoate (B4) showed a smaller HOMO-LUMO energy gap suggests higher chemical reactivity and lower kinetic stability, and a strong binding affinity (-8.3 kcal/mol) to the target protein in comparison to Chloroquine (-5.9 kcal/mol) and Lumefantrine (-7.3 kcal/mol). Thus, the 4-Hydroxyphenyl-3-nitrobenzoate (-8.3 kcal/mol) B4 may serve as a preliminary candidate identified via in silico screening and can also be investigated for antimalarial drug development.
No takes yet. Share an insight, caveat, or question.
Olarinoye et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: